“Sustained On- and Off-Treatment Disease Control in Patients With Moderate-to-Severe Atopic Dermatitis Following 12-Week, Open-Label, Once-Daily Abrocitinib 200 mg: A Post Hoc Analysis of the Phase 3 JADE REGIMEN Study”, J of Skin, vol. 10, no. 2, p. s732, Mar. 2026, doi: 10.25251/v9pqj003.